|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
|
|---|---|---|
| ASSETS | ||
| Current | ||
| Cash and cash equivalents (note 4) | ||
| Trade and other receivables | ||
| Inventories (note 5) | ||
| Investments-equity instruments | ||
| Investments-equity instruments (note 6) | ||
| Investments-uranium (note 6) | ||
| Total investments-equity instruments | ||
| Prepaid expenses and other | ||
| Total current assets | ||
| Non-Current | ||
| Inventories-ore in stockpiles (note 5) | ||
| Investments-equity instruments (note 6) | ||
| Investments-uranium | ||
| Investments-convertible debentures | ||
| Investments-joint venture | ||
| Restricted cash and investments | ||
| Investments-uranium (note 6) | ||
| Investments-debt instruments (note 6) | ||
| Capped Call derivative options (note 14) | ||
| Investments-joint venture (note 7) | ||
| Restricted cash and investments (note 8) | ||
| Property, plant and equipment (note 9) | ||
| Other long-term assets | ||
| Total assets | ||
| LIABILITIES | ||
| Current | ||
| Accounts payable and accrued liabilities | ||
| Accounts payable and accrued liabilities (note 10) | ||
| Current portion of long-term liabilities: | ||
| Deferred revenue (note 11) | ||
| Reclamation obligations (note 12) | ||
| Other liabilities (note 13) | ||
| Total current liabilities | ||
| Non-Current | ||
| Deferred revenue (note 11) | ||
| Reclamation obligations (note 12) | ||
| Convertible Notes (note 14) | ||
| Other liabilities (note 13) | ||
| Deferred income tax liability | ||
| Deferred income tax liability (note 15) | ||
| Total liabilities | ||
| EQUITY | ||
| Share capital (note 16) | ||
| Contributed surplus | ||
| Deficit | ||
| Accumulated other comprehensive income (note 18) | ||
| Total equity | ||
| Total liabilities and equity | ||
| Issued and outstanding common shares (note 16) |
Loading...
